



UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

FEBRUARY 26, 2025

PTAS

BRENT R. BELLOWS
400 PERIMETER CENTER TERRACE
SUITE 200
ATLANTA, GA 30346

509046852

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT RECORDATION BRANCH OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE ASSIGNMENT RECORDATION BRANCH AT 571-272-3350. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT RECORDATION BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313.

RECORDATION DATE: 02/25/2025

REEL/FRAME: 070324/0765
NUMBER OF PAGES: 4

BRIEF: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

DOCKET NUMBER: 12020-049W01_W01US1

ASSIGNOR:

THE CENTRE NATIONAL DE LA RECHERCHE
SCIENTIFIQUE

DOC DATE: 02/21/2025

ASSIGNEE:

ATEA PHARMACEUTICALS, INC.
225 FRANKLIN STREET
SUITE 2100
BOSTON, MASSACHUSETTS 02110

APPLICATION NUMBER: 18957362

FILING DATE: 11/22/2024

PATENT NUMBER:

ISSUE DATE:

TITLE: DOSAGE REGIMENS FOR TREATMENT OF DENGUE INFECTION

APPLICATION NUMBER:

FILING DATE: 05/26/2023

PATENT NUMBER:

ISSUE DATE:

PCT NUMBER: US2323739

TITLE: DOSAGE REGIMENS FOR TREATMENT OF DENGUE INFECTION

ASSIGNMENT RECORDATION BRANCH
PUBLIC RECORDS DIVISION

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

Assignment ID: PATI847707

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNMENT		
CONVEYING PARTY DATA			
Name			Execution Date
The Centre National de la Recherche Scientifique			02/21/2025
RECEIVING PARTY DATA			
Company Name:	Atea Pharmaceuticals, Inc.		
Street Address:	225 Franklin Street		
Internal Address:	Suite 2100		
City:	Boston		
State/Country:	MASSACHUSETTS		
Postal Code:	02110		
PROPERTY NUMBERS Total: 2			
Property Type	Number		
PCT Number:	US2323739		
Application Number:	18957362		
CORRESPONDENCE DATA			
Fax Number:	4046015838		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	6789410190		
Email:	docket@kipsllc.com		
Correspondent Name:	Brent R. Bellows		
Address Line 1:	400 Perimeter Center Terrace		
Address Line 2:	Suite 200		
Address Line 4:	Atlanta, GEORGIA 30346		
ATTORNEY DOCKET NUMBER:	12020-049WO1_WO1US1		
NAME OF SUBMITTER:	Brent Bellows		
SIGNATURE:	/Brent Bellows/		
DATE SIGNED:	02/25/2025		
Total Attachments: 3			
source=12020-049WO1 CNRS_to_Atea_Confirmatory Assignment FULLY EXECUTED_2025-02-24#page1.tiff			
source=12020-049WO1 CNRS_to_Atea_Confirmatory Assignment FULLY EXECUTED_2025-02-24#page2.tiff			
source=12020-049WO1 CNRS_to_Atea_Confirmatory Assignment FULLY EXECUTED_2025-02-24#page3.tiff			

CONFIRMATORY ASSIGNMENT

WHEREAS, **THE CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE**, a business entity organized and existing under the laws of France, having its principal place of business at rue Michel Ange, 75794 Paris Cedex 16, France (hereinafter “**ASSIGNOR**”), owns, by virtue of employing a named inventor, certain inventions and improvements disclosed in PCT Patent Application titled “**DOSAGE REGIMENS FOR TREATMENT OF DENGUE INFECTION**,” filed in the United States Patent and Trademark Office acting as the Receiving Office on **May 26, 2023**, and assigned PCT Application No. **PCT/US23/23739** (“**PCT Application**”), which claims priority to U.S. Provisional Patent Applications titled “**DOSAGE REGIMENS FOR TREATMENT OR PROPHYLAXIS OF DENGUE INFECTION**,” which are identified in the United States Patent and Trademark Office by Provisional Application Nos. **63/346,274**, filed on **May 26, 2022**; **63/414,812**, filed on **October 10, 2022**; and **63/427,359**, filed on **November 22, 2022**, and for which an application for Letters Patent in the United States and/or other foreign jurisdictions claiming priority to said PCT Application will be made.

WHEREAS, **ATEA PHARMACEUTICALS, INC.** (“**ASSIGNEE**”), a business entity organized and existing under the laws of the state of Delaware, and having its principal offices at 225 Franklin Street, Suite 2100, Boston, Massachusetts 02110, is entitled to the ownership of these inventions and improvements and all applications describing these inventions and improvements, by virtue of a contractual agreement, and thus desires to acquire, or to the extent already done so, then to confirm the acquisition of the entire right, title, and interest in and to said inventions, improvements, know-how, and said PCT Application and to the Letters Patent which may be granted therefrom.

NOW, THEREFORE, for good and valuable consideration previously received, the receipt and sufficiency of which is hereby acknowledged, **ASSIGNOR** by these presents does sell, assign, and transfer, or to the extent already done so, then confirms the sale, assignment, and transfer, to **ASSIGNEE** the full, exclusive, and entire right, title, and interest in and to all inventions and improvements disclosed and described in said PCT Application, as well as all know-how derived during the development of, and directed to, the inventions and improvements disclosed and described in said PCT Application.

For the same consideration, **ASSIGNOR**, by these presents, does sell, assign, and transfer, or to the extent already done so then confirms the sale, assignment, and transfer, to **ASSIGNEE**, the full, exclusive, and entire right, title, and interest in and to any U.S. nonprovisional or foreign application or any other applications that correspond to or claim priority to said PCT Application, in whole or in part, and to any

Letters Patent and similar protective rights granted on said U.S. nonprovisional or foreign applications, and in and to the right to claim any applicable priority rights arising from or required for said U.S. nonprovisional or foreign applications under the terms of any applicable conventions, treaties, statutes, or regulations, including to all divisions, continuations, continuations-in-part, or renewals thereof, all Letters Patent which may be granted therefrom, all reexaminations, and all reissues or extensions of such patents; said U.S. nonprovisional or foreign applications to be filed and issued in the name of ASSIGNEE or its designee insofar as permitted by applicable law;

AND, for the consideration aforesaid, ASSIGNOR does hereby confirm its agreement that it or its executor(s) and legal representatives will make, execute and deliver any and all other instruments in writing including any and all further application papers, affidavits, assignments and other documents, and will communicate to said ASSIGNEE, its successors and representatives all facts known to ASSIGNOR relating to said inventions and improvements and the history thereof and will testify in all legal proceedings and generally do all things which may be necessary or desirable more effectually to secure to and vest in said ASSIGNEE, its successors or assigns the entire right, title, and interest in and to the said improvements, inventions, know how, applications, Letters Patent, rights, titles, benefits, privileges and advantages hereby assigned and conveyed, or intended so to be;

AND, furthermore, ASSIGNOR covenants and agrees, or to the extent already done so then confirms its covenant and agreement, with said ASSIGNEE, its successors and assigns, that no assignment, grant, mortgage, license or other agreement affecting the rights and property herein conveyed has been made to others by ASSIGNOR and that full right to convey the same as herein expressed is possessed by ASSIGNOR.

12020-0

Date:

2/02/25

Title:

IP Administrator

Date:

21 Februar 2025

Title:

CFO And EOP, Legal